Clinical Research
Filter News
Found 126,166 articles
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
Sponsored | Business Transformation during a Pandemic: Q&A about Jubilant Biosys’ bold plans wit...
4/22/2021
This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagu... -
Simply put, an antibody is a large, Y-shaped blood protein produced by plasma cells that the immune system uses to take down pathogens like bacteria – and of course, viruses like SARS-CoV-2.
-
Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year
4/22/2021
Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic tests worth 16,209,150 GBP to Scotland under a public procurement agreement, the largest diagnostic volume seen in that r
-
New Analysis Shows International Reference Drug Pricing Would Have a Catastrophic Impact on Alzheimer's Disease Research
4/22/2021
The number of Americans aged 65 and older with Alzheimer's disease (AD) is expected to more than double from 6.2 million today to 12.7 million by 2050.
-
Agilent LC/MS Instruments Receive ACT Labels from My Green Lab
4/22/2021
Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
-
Data from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology
4/22/2021
Codiak BioSciences, Inc., a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication.
-
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
4/22/2021
YTX-7739 is Yumanity’s lead product candidate in clinical development for the treatment of Parkinson’s disease
-
Bio-Path Announces Publication in Biomedicines
4/22/2021
Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen
-
Lexaria Commences Human Clinical Hypertension Study
4/22/2021
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway.
-
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
4/22/2021
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases.
-
Can-Fite Expands its Phase II COVID-19 Study to Europe
4/22/2021
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomi
-
A small study by researchers in Israel published in the journal Rheumatology identified six cases of patients developing herpes zoster rashes (shingles) after receiving the Pfizer-BioNTech vaccine.
-
AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More
4/21/2021
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them. -
Beam Therapeutics has recently unveiled a new CRISPR base editing tool to target sickle cell mutations, a promising approach that holds substantial clinical value for patients with these blood disorders.
-
A $25 million grant from the National Institutes of Health Helping to End Addiction Long-term Initiative (HEAL) is funding new research to develop a vaccine that may help patients overcome their addiction to opioids, a class of highly addictive pain medications.
-
Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research
4/21/2021
Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, announced the close of a $40 million Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.
-
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
4/21/2021
Ainos, Inc., f/k/a Amarillo Biosciences, Inc.(OTCBB:AMAR), a company engaged in the discovery and development of pharmaceutical and biotech products, announced today that it has consummated the transaction pursuant to that certain Securities Purchase Agreement dated December 24, 2020 with a strategic investor, Ainos, Inc., a Cayman Islands corporation
-
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
4/21/2021
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp.
-
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
4/21/2021
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the publication of results from the company’s CLASSICAL-Lung clinical trial in the journal Clinical Cancer Research , a publication of the American Association for Cancer Research (AACR).